I came to London to report about higher education but I stayed for the austerity.

AstraZeneca Earnings Beat Estimates as New Drugs Take Hold

bloomberg.com — AstraZeneca Plc, the U.K.'s second-largest drugmaker, reported core operating profit that beat analysts' estimates in the second quarter as sales of diabetes treatments and the blood thinner Brilinta helped offset declines in older medicines. Profit excluding some items was $1.81 billion, or $1.21 a share, compared with $2.03 billion, or $1.30 a share, a year earlier, the London-based company said in a statement.
Jul 30, 2015

$AZN manages to beat estimates, as new drugs show gains and old one do better than expected bloomberg.com/news/articles/…

Glaxo Aims for Next Wave of Cancer Drugs After Missing First

bloomberg.com — GlaxoSmithKline Plc shed more light on its pipeline of experimental medicines, giving a glimpse of drugs in earlier stages of development, although analysts remain skeptical about their promise. Glaxo has 40 drugs in the middle or final stages of clinical trials, Chief Executive Officer Andrew Witty said on Wednesday, and about half may be submitted to regulators or approved by 2020.

Glaxo Earnings Beat Estimates on AIDS Drugs, Cost Reductions

bloomberg.com — GlaxoSmithKline Plc, the U.K.'s biggest drugmaker, reported second-quarter earnings that declined less than analysts had estimated as AIDS medicines and efforts to reduce costs offset slumping revenue from Advair, its best-selling asthma drug. Profit excluding certain items was 1.3 billion pounds ($2.1 billion), or 17.3 pence a share, down from 1.4 billion pounds, or 19.1 pence a share, a year ago, the London-based company said today.

Sorin Slumps as Milan Court Casts Doubt on Cyberonics Deal

bloomberg.com — Sorin SpA had the biggest decline in almost seven years after the state's attorney in Milan filed a claim against the company that may delay its plans to combine with Cyberonics Inc. The state attorney views the planned transaction as intended to insulate Milan-based Sorin from potential liability related to environmental litigation against its previous parent, SNIA SpA, the combining companies said in a statement.

Finally! First malaria vaccine gets the nod after a 28-year journey

mgafrica.com — THE world's first vaccine for malaria has won the backing of European regulators, a critical step toward widespread immunisation against a disease that takes half a million lives every year in Africa. The Mosquirix vaccine from GlaxoSmithKline has been under development for 28 years.
Jul 25, 2015

Finally! First malaria vaccine gets the nod after a 28-year journey | Mail & Guardian Africa mgafrica.com/article/2015-0…

Jul 25, 2015

RT @cobbo3: Finally! First malaria vaccine gets the nod after a 28-year journey | Mail & Guardian Africa mgafrica.com/article/2015-0…

First Malaria Vaccine Gains Recommendation After 28-Year Odyssey

bloomberg.com — The world's first vaccine for malaria won the backing of European regulators, a critical step toward widespread immunization against a disease that takes half a million lives a year. The Mosquirix vaccine from GlaxoSmithKline Plc has been under development for 28 years.
Jul 24, 2015

It took 28 years, but first #malaria vaccine is approved. Potential game changer in fight against killer disease. bloomberg.com/news/articles/…

Jul 24, 2015

$AGEN, made with Agenus' adjuvant...First Malaria Vaccine Gains Recommendation After 28-Year Odyssey bloom.bg/1DAuvOz via @business

Jul 24, 2015

It took 28 years, but first-ever #malaria vaccine is approved. A triumph for global health and $GSK. My story: bloomberg.com/news/articles/…

Jul 24, 2015

RT @sbancel: First #Malaria Vaccine Gains Recommendation After 28-Year Odyssey. A big step forward for Public Health! bloom.bg/1DAuvOz

Jul 24, 2015

It took 28 years for $GSK to develop world's first vaccine for #malaria, a killer of 500K children annually bloomberg.com/news/articles/…

Actelion Raises Forecast Amid Higher Sales of New Medicine

bloomberg.com — Actelion Ltd. boosted its earnings forecast and Chief Executive Officer Jean-Paul Clozel said he wasn't interested in selling the Swiss drugmaker following a newspaper report that it spurned an advance from Shire Plc. "I do not see a reason to sell a company when we are delivering such good results," Clozel said in a phone interview Tuesday.

Success at Glaxo’s HIV Unit May Mean Having to Call It Quits

bloomberg.com — HIV drugs are proving to be so effective in containing the virus that GlaxoSmithKline Plc foresees a time, a decade away, when its most profitable business unit may no longer have a purpose. "There are diminishing returns in HIV," said David Redfern, Glaxo's chief strategy officer and the chairman of its AIDS treatment unit ViiV Healthcare Ltd.
Jul 09, 2015

Can #HIV drugs be too effective? The success of ViiV, $GSK's AIDS unit, may put it out of business. My story: bloomberg.com/news/articles/…

Jul 09, 2015

The #HIV drugs of $GSK's ViiV may be so good, they'll put the unit out of business. My story: bloomberg.com/news/articles/… @business

Jul 09, 2015

#AIDS drugs are so effective, their success may lead to the demise of @ViiVHC, $GSK's HIV business. My story: bloomberg.com/news/articles/…

Show 1 more tweet from Harry R. Weber

Unemployed Greeks Reconnect as Underground Electricians Defy Law

bloomberg.com — Dec. 5 (Bloomberg) -- Kostas Ioannidis, an unemployed metalworker with an ailing mother and disabled wife, can't afford electricity. So he steals it instead. Like thousands of other Greeks, Ioannidis had his power disconnected because he couldn't pay his bills. He owes 2,700 euros ($3,668) and can't make even the 150 euro monthly payments he negotiated with the power company.
Jul 06, 2015

Correction: 2013 //in 2003 story about Greeks stealing electricity, I quoted new finance minister Euclid Tsakalotos bloomberg.com/news/articles/…

Jul 06, 2015

“We see civil disobedience as a bona fide part of European culture” Greece's new finance minister told me in 2013 bloomberg.com/news/articles/…

Jul 06, 2015

For a 2003 story about destitute Greeks stealing electricity, I quoted new finance minister Euclid Tsakalotos bloomberg.com/news/articles/…

Jul 06, 2015

RT @Ostaley: For a 2003 story about destitute Greeks stealing electricity, I quoted new finance minister Euclid Tsakalotos bloomberg.com/news/articles/…

Jul 06, 2015

RT @Ostaley: For a 2003 story about destitute Greeks stealing electricity, I quoted new finance minister Euclid Tsakalotos bloomberg.com/news/articles/…

Raging bull markets: How young men's hormones unsettle finance

denverpost.com — Researchers say cortisol and testosterone spur young, male traders to take risks - and keep taking them Posted: 07/05/2015 12:01:00 AM MDT NEW YORK - Want to calm financial markets? Add more women and older people to the young men on trading desks.
More Articles →
Jul 30, 2015

Was just interviewed for Bloomberg Radio by the guy who tells New York commuters "Stand Clear of the Closing Doors" ritholtz.com/blog/2013/11/c…

Jul 30, 2015

$AZN manages to beat estimates, as new drugs show gains and old one do better than expected bloomberg.com/news/articles/…

Jul 30, 2015

Today's financial jargon, "footprint optimisation," is brought to you by @AstraZeneca

Jul 29, 2015

16 years ago, James Wilson's gene therapy killed a patient. Now he's at center of biotech boom. via @RobertLangreth bloomberg.com/news/articles/…

Jul 29, 2015

Separated at birth? Former @CPFC manager Ian Holloway and @GSK chairman Phil Hampton are doppelgangers pic.twitter.com/Jx3sccW9y9



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.